A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD)
Barnett S. Meyers*, Alastair J. Flint, Anthony J. Rothschild, Benoit H. Mulsant, Ellen M. Whyte, Catherine Peasley-Miklus, Eros Papademetriou, Andrew C. Leon, Moonseong Heo, G. S. Alexopoulos, M. L. Bruce, S. Klimstra, J. English, M. Gabriele, F. Santana, G. Addonizio, J. De Asis, X. Y. Baran, B. Kalyam, D. J. KupferM. E. Thase, D. J. Cohen, J. E. Emanuel, T. S. Kamara, B. Kephart, E. R. Mathis, N. M. McLaughlin, M. McShea, A. G. Gildengers, R. H. Howland, M. D. Miller, J. Rosen, P. Appelbaum, P. J. Candilis, D. Guerin, C. Wood, A. Rohrbaugh, S. Fratoni, C. Calkins, J. Grogan, M. Martin, J. Patel, E. Smith, R. Reni, D. Sit, E. Kayatekin, D. Morin, C. Cimpeanu, T. Shteinlukht, M. Vemuri, The STOP-PD Group
Dive into the research topics of 'A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD)'. Together they form a unique fingerprint.